In Russia nowadays there are effective organizations of pharmacovigilance. The monitoring of adverse reactions in various forms is carried out, including active prospective monitoring (the method considered the most comprehensive and providing identification of the maximum amount of the ADR, to assess fully the risks associated with the use of the medicinal product). The existence of a well-functioning structure for timely detection of adverse reactions has certain advantages for post-marketing Phase IV clinical trials.